Can we use Ki67 expression to predict prostate cancer aggressiveness?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista do Colégio Brasileiro de Cirurgiões |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912022000100220 |
Resumo: | ABSTRACT Introduction: specialists have an urge for biomarkers that can discriminate indolent prostate cancer from aggressive tumors. Ki67 is a proliferation marker, and its expression is associated with the aggressiveness of several cancers. Objective: analyze the expression of Ki67 in prostate cancer samples correlating with the aggressiveness of the disease. Methods: Ki67 mRNA levels were determined utilizing data from a TCGA cohort (Tumor(n)=492 and control(n)=52). The protein expression was determined on 94 biopsies from patients by immunohistochemical assay. Results: in mRNA, the Ki67 upregulation is associated with cancer tissue (p<0.0001) and worst disease-free survival (p=0.035). The protein upregulation is associated with increase of the ISUP score (p<0.0001), cancer stage (p=0.05), biochemical recurrence (p=0.0006) and metastasis (p<0.0001). We also show a positive correlation between Ki67 expression and ISUP score (r=0.5112, p<0.0001) and disease risk stratification (r=0.3388, p=0.0009). Ki67 expression is a factor independently associated with biochemical recurrence (p=0.002) and metastasis (p<0.0001). Finally, the patients with high Ki67expression shows better survival regarding biochemical recurrence (p=0.008) and metastasis (p=0.056). Patients with high Ki67 expression are 2.62 times more likely to develop biochemical recurrence (p=0.036). Conclusion: Ki67 upregulation is associated with prostate cancer aggressiveness. |
id |
CBC-1_0cd79af52b87342753fd3365e55f69bc |
---|---|
oai_identifier_str |
oai:scielo:S0100-69912022000100220 |
network_acronym_str |
CBC-1 |
network_name_str |
Revista do Colégio Brasileiro de Cirurgiões |
repository_id_str |
|
spelling |
Can we use Ki67 expression to predict prostate cancer aggressiveness?Biomarkers, TumorPrognosisImmunoassayABSTRACT Introduction: specialists have an urge for biomarkers that can discriminate indolent prostate cancer from aggressive tumors. Ki67 is a proliferation marker, and its expression is associated with the aggressiveness of several cancers. Objective: analyze the expression of Ki67 in prostate cancer samples correlating with the aggressiveness of the disease. Methods: Ki67 mRNA levels were determined utilizing data from a TCGA cohort (Tumor(n)=492 and control(n)=52). The protein expression was determined on 94 biopsies from patients by immunohistochemical assay. Results: in mRNA, the Ki67 upregulation is associated with cancer tissue (p<0.0001) and worst disease-free survival (p=0.035). The protein upregulation is associated with increase of the ISUP score (p<0.0001), cancer stage (p=0.05), biochemical recurrence (p=0.0006) and metastasis (p<0.0001). We also show a positive correlation between Ki67 expression and ISUP score (r=0.5112, p<0.0001) and disease risk stratification (r=0.3388, p=0.0009). Ki67 expression is a factor independently associated with biochemical recurrence (p=0.002) and metastasis (p<0.0001). Finally, the patients with high Ki67expression shows better survival regarding biochemical recurrence (p=0.008) and metastasis (p=0.056). Patients with high Ki67 expression are 2.62 times more likely to develop biochemical recurrence (p=0.036). Conclusion: Ki67 upregulation is associated with prostate cancer aggressiveness.Colégio Brasileiro de Cirurgiões2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912022000100220Revista do Colégio Brasileiro de Cirurgiões v.49 2022reponame:Revista do Colégio Brasileiro de Cirurgiõesinstname:Colégio Brasileiro de Cirurgiões (CBC)instacron:CBC10.1590/0100-6991e-20223200-eninfo:eu-repo/semantics/openAccessMAIA,RONALDOSANTOS,GABRIEL ARANTES DOSREIS,SABRINAVIANA,NAYARA IPIMENTA,RUANGUIMARÃES,VANESSA RRECUERO,SAULOROMÃO,POLIANALEITE,KATIA RAMOS MOREIRASROUGI,MIGUELPASSEROTTI,CARLO CARMARGOeng2022-06-27T00:00:00Zoai:scielo:S0100-69912022000100220Revistahttp://www.scielo.br/rcbcONGhttps://old.scielo.br/oai/scielo-oai.php||revistacbc@cbc.org.br1809-45460100-6991opendoar:2022-06-27T00:00Revista do Colégio Brasileiro de Cirurgiões - Colégio Brasileiro de Cirurgiões (CBC)false |
dc.title.none.fl_str_mv |
Can we use Ki67 expression to predict prostate cancer aggressiveness? |
title |
Can we use Ki67 expression to predict prostate cancer aggressiveness? |
spellingShingle |
Can we use Ki67 expression to predict prostate cancer aggressiveness? MAIA,RONALDO Biomarkers, Tumor Prognosis Immunoassay |
title_short |
Can we use Ki67 expression to predict prostate cancer aggressiveness? |
title_full |
Can we use Ki67 expression to predict prostate cancer aggressiveness? |
title_fullStr |
Can we use Ki67 expression to predict prostate cancer aggressiveness? |
title_full_unstemmed |
Can we use Ki67 expression to predict prostate cancer aggressiveness? |
title_sort |
Can we use Ki67 expression to predict prostate cancer aggressiveness? |
author |
MAIA,RONALDO |
author_facet |
MAIA,RONALDO SANTOS,GABRIEL ARANTES DOS REIS,SABRINA VIANA,NAYARA I PIMENTA,RUAN GUIMARÃES,VANESSA R RECUERO,SAULO ROMÃO,POLIANA LEITE,KATIA RAMOS MOREIRA SROUGI,MIGUEL PASSEROTTI,CARLO CARMARGO |
author_role |
author |
author2 |
SANTOS,GABRIEL ARANTES DOS REIS,SABRINA VIANA,NAYARA I PIMENTA,RUAN GUIMARÃES,VANESSA R RECUERO,SAULO ROMÃO,POLIANA LEITE,KATIA RAMOS MOREIRA SROUGI,MIGUEL PASSEROTTI,CARLO CARMARGO |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
MAIA,RONALDO SANTOS,GABRIEL ARANTES DOS REIS,SABRINA VIANA,NAYARA I PIMENTA,RUAN GUIMARÃES,VANESSA R RECUERO,SAULO ROMÃO,POLIANA LEITE,KATIA RAMOS MOREIRA SROUGI,MIGUEL PASSEROTTI,CARLO CARMARGO |
dc.subject.por.fl_str_mv |
Biomarkers, Tumor Prognosis Immunoassay |
topic |
Biomarkers, Tumor Prognosis Immunoassay |
description |
ABSTRACT Introduction: specialists have an urge for biomarkers that can discriminate indolent prostate cancer from aggressive tumors. Ki67 is a proliferation marker, and its expression is associated with the aggressiveness of several cancers. Objective: analyze the expression of Ki67 in prostate cancer samples correlating with the aggressiveness of the disease. Methods: Ki67 mRNA levels were determined utilizing data from a TCGA cohort (Tumor(n)=492 and control(n)=52). The protein expression was determined on 94 biopsies from patients by immunohistochemical assay. Results: in mRNA, the Ki67 upregulation is associated with cancer tissue (p<0.0001) and worst disease-free survival (p=0.035). The protein upregulation is associated with increase of the ISUP score (p<0.0001), cancer stage (p=0.05), biochemical recurrence (p=0.0006) and metastasis (p<0.0001). We also show a positive correlation between Ki67 expression and ISUP score (r=0.5112, p<0.0001) and disease risk stratification (r=0.3388, p=0.0009). Ki67 expression is a factor independently associated with biochemical recurrence (p=0.002) and metastasis (p<0.0001). Finally, the patients with high Ki67expression shows better survival regarding biochemical recurrence (p=0.008) and metastasis (p=0.056). Patients with high Ki67 expression are 2.62 times more likely to develop biochemical recurrence (p=0.036). Conclusion: Ki67 upregulation is associated with prostate cancer aggressiveness. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912022000100220 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912022000100220 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/0100-6991e-20223200-en |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Colégio Brasileiro de Cirurgiões |
publisher.none.fl_str_mv |
Colégio Brasileiro de Cirurgiões |
dc.source.none.fl_str_mv |
Revista do Colégio Brasileiro de Cirurgiões v.49 2022 reponame:Revista do Colégio Brasileiro de Cirurgiões instname:Colégio Brasileiro de Cirurgiões (CBC) instacron:CBC |
instname_str |
Colégio Brasileiro de Cirurgiões (CBC) |
instacron_str |
CBC |
institution |
CBC |
reponame_str |
Revista do Colégio Brasileiro de Cirurgiões |
collection |
Revista do Colégio Brasileiro de Cirurgiões |
repository.name.fl_str_mv |
Revista do Colégio Brasileiro de Cirurgiões - Colégio Brasileiro de Cirurgiões (CBC) |
repository.mail.fl_str_mv |
||revistacbc@cbc.org.br |
_version_ |
1754209215442845696 |